Bridging the gap from medical to psychological safety assessment: consensus study in a digital mental health context.

Digital mental health interventions MHRA consensus mental health safety

Journal

BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931

Informations de publication

Date de publication:
03 Jun 2024
Historique:
medline: 3 6 2024
pubmed: 3 6 2024
entrez: 3 6 2024
Statut: epublish

Résumé

Digital Mental Health Interventions (DMHIs) that meet the definition of a medical device are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. The MHRA uses procedures that were originally developed for pharmaceuticals to assess the safety of DMHIs. There is recognition that this may not be ideal, as is evident by an ongoing consultation for reform led by the MHRA and the National Institute for Health and Care Excellence. The aim of this study was to generate an experts' consensus on how the medical regulatory method used for assessing safety could best be adapted for DMHIs. An online Delphi study containing three rounds was conducted with an international panel of 20 experts with experience/knowledge in the field of UK digital mental health. Sixty-four items were generated, of which 41 achieved consensus (64%). Consensus emerged around ten recommendations, falling into five main themes: Enhancing the quality of adverse events data in DMHIs; Re-defining serious adverse events for DMHIs; Reassessing short-term symptom deterioration in psychological interventions as a therapeutic risk; Maximising the benefit of the Yellow Card Scheme; and Developing a harmonised approach for assessing the safety of psychological interventions in general. The implementation of the recommendations provided by this consensus could improve the assessment of safety of DMHIs, making them more effective in detecting and mitigating risk.

Sections du résumé

BACKGROUND BACKGROUND
Digital Mental Health Interventions (DMHIs) that meet the definition of a medical device are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. The MHRA uses procedures that were originally developed for pharmaceuticals to assess the safety of DMHIs. There is recognition that this may not be ideal, as is evident by an ongoing consultation for reform led by the MHRA and the National Institute for Health and Care Excellence.
AIMS OBJECTIVE
The aim of this study was to generate an experts' consensus on how the medical regulatory method used for assessing safety could best be adapted for DMHIs.
METHOD METHODS
An online Delphi study containing three rounds was conducted with an international panel of 20 experts with experience/knowledge in the field of UK digital mental health.
RESULTS RESULTS
Sixty-four items were generated, of which 41 achieved consensus (64%). Consensus emerged around ten recommendations, falling into five main themes: Enhancing the quality of adverse events data in DMHIs; Re-defining serious adverse events for DMHIs; Reassessing short-term symptom deterioration in psychological interventions as a therapeutic risk; Maximising the benefit of the Yellow Card Scheme; and Developing a harmonised approach for assessing the safety of psychological interventions in general.
CONCLUSION CONCLUSIONS
The implementation of the recommendations provided by this consensus could improve the assessment of safety of DMHIs, making them more effective in detecting and mitigating risk.

Identifiants

pubmed: 38828683
doi: 10.1192/bjo.2024.713
pii: S2056472424007130
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e126

Auteurs

Rayan Taher (R)

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.

Palak Bhanushali (P)

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.

Stephanie Allan (S)

Institute of Health and Wellbeing, University of Glasgow, UK.

Mario Alvarez-Jimenez (M)

Centre for Youth Mental Health, University of Melbourne, Australia.
Orygen, Parkville, Australia.

Heather Bolton (H)

Unmind, London, UK.

Laura Dennison (L)

School of Psychology, University of Southampton, UK.

Brian E Wallace (BE)

Calmsie, Warsaw, Poland.

Heather D Hadjistavropoulos (HD)

Department of Psychology, University of Regina, Canada.

Charlotte L Hall (CL)

NIHR MindTech-MedTech Co-operative, NIHR Nottingham Biomedical Research Centre, School of Medicine, Institute of Mental Health, University of Nottingham, UK.

Amy Hardy (A)

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.

Sam Lane (S)

SilverCloud by Amwell, Boston, USA.

Tess Maguire (T)

School of Psychology, University of Southampton, UK.

Adam Moreton (A)

ORCHA, Daresbury, UK.

Talar R Moukhtarian (TR)

Mental Health and Wellbeing Unit, Warwick Medical School, University of Warwick, UK.

Elvira Perez Vallejos (EP)

NIHR MindTech-MedTech Co-operative, NIHR Nottingham Biomedical Research Centre, School of Medicine, Institute of Mental Health, University of Nottingham, UK.

Sukhi Shergill (S)

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.
Kent and Medway Medical School, Canterbury, UK.

Daniel Stahl (D)

Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.

Graham R Thew (GR)

Department of Experimental Psychology, University of Oxford, UK.
Oxford Health NHS Foundation Trust, Oxford, UK.

Ladislav Timulak (L)

School of Psychology, Trinity College Dublin, Ireland.

David van den Berg (D)

Department of Clinical Psychology, VU University and Amsterdam Public Health Research, Amsterdam, Netherlands.

Noemi Viganò (N)

SilverCloud by Amwell, Boston, USA.

Ben Wensley Stock (BW)

University of Oxford Medical Sciences Division, University of Oxford, UK.

Katherine S Young (KS)

SilverCloud by Amwell, Boston, USA.
Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.

Jenny Yiend (J)

Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK.

Classifications MeSH